Stock analysts at SVB Leerink initiated coverage on shares of Eli Lilly and (NYSE:LLY – Get Rating) in a note issued to investors on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.
LLY has been the subject of several other research reports. Wells Fargo & Company boosted their target price on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Mizuho boosted their price objective on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Morgan Stanley boosted their price objective on Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Bank of America boosted their price objective on Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $302.56.
Shares of LLY opened at $298.85 on Monday. The stock has a 50-day simple moving average of $292.36 and a 200-day simple moving average of $267.87. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a market capitalization of $283.96 billion, a PE ratio of 44.27, a PEG ratio of 2.27 and a beta of 0.40. Eli Lilly and has a 1 year low of $195.50 and a 1 year high of $314.00.
In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $243.84, for a total transaction of $404,774.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 139,045 shares of the stock in a transaction dated Friday, April 8th. The shares were sold at an average price of $310.79, for a total value of $43,213,795.55. Following the completion of the sale, the insider now owns 105,573,810 shares of the company’s stock, valued at approximately $32,811,284,409.90. The disclosure for this sale can be found here. Insiders have sold 1,169,012 shares of company stock worth $332,350,306 over the last quarter. 0.12% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Eli Lilly and by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock valued at $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. State Street Corp lifted its holdings in Eli Lilly and by 2.5% during the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after buying an additional 813,983 shares during the last quarter. Capital World Investors lifted its holdings in Eli Lilly and by 17.0% during the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after buying an additional 3,242,548 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Eli Lilly and by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock worth $4,059,130,000 after buying an additional 409,009 shares during the last quarter. Finally, Capital International Investors lifted its holdings in Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after buying an additional 2,063,557 shares during the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.
Eli Lilly and Company Profile (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.